Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase Journal Article uri icon
  • OBJECTIVE To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained use of SAP. RESEARCH DESIGN AND METHODS The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P < 0.001). A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P < 0.001); this was a significant and sustained decrease among both adults and children (P < 0.05). CONCLUSIONS Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.

  • Link to Article
    publication date
  • 2011
  • published in
  • Diabetes care  Journal
  • Research
  • Blood
  • Cross-Over Studies
  • Diabetes
  • Drugs and Drug Therapy
  • Randomized Controlled Trials
  • Additional Document Info
  • 34
  • issue
  • 11